Clinical Trials Logo
  1. Home
  2. Other
  3. NCT05137522

Chidamide Combines With VP-16 and Methylprednisolone in the Treatment of HLH

Hemophagocytic Lymphohistiocytosis Clinical Trial

Official title:
Chidamide Combines With Etoposide and Methylprednisolone in the Treatment of Hemophagocytic Lymphohistiocytosis

Clinical Trial Summary

Chidamide combines with VP-16 and methylprednisolone in HLH

Clinical Trial Description

This study aimed to investigate the efficacy and safety of Chidamide together with Etoposide and methylprednisolone for hemophagocytic lymphohistiocytosis ;

Study Design

Related Conditions & MeSH terms

  • Chidamide
  • Hemophagocytic Lymphohistiocytosis
  • Lymphohistiocytosis, Hemophagocytic
Clinical Trial Details
NCT number NCT05137522
Study type Interventional
Source Beijing Friendship Hospital
Contact Wang Zhao
Phone 86-010-63139862
Email wangzhao@ccmu.edu.cn
Status Recruiting
Phase N/A
Start date July 1, 2021
Completion date July 1, 2023
View Details
See also
  Status Clinical Trial Phase
Recruiting NCT01652092 - Allogeneic Hematopoietic Stem Cell Transplant for Patients With Primary Immune Deficiencies N/A
Recruiting NCT02912702 - L-DEP as an Initial Treatment for EBV-HLH Phase 3
Terminated NCT00176826 - T-Cell Depletion and Stem Cell Transplant for Immune Deficiencies and Histiocytic Disorders Phase 2/Phase 3
Not yet recruiting NCT06038422 - GTP Regimen in the Treatment of Refractory/Recurrent HLH Phase 3
Completed NCT03510650 - Diagnostic Biomarkers for Adult Hemophagocytic Lymphohistiocytosis in Critically Ill Patients (HEMICU)
Completed NCT03259230 - Study to Evaluate Interferon Gamma (IFNγ) and Other Inflammatory Mediators in Patients With Malignancy-Associated Hemophagocytic Lymphohistiocytosis (M-HLH)
Active, not recruiting NCT01494103 - Administration of Donor T Cells With the Caspase-9 Suicide Gene Phase 1
Recruiting NCT05164978 - DEP Combine With PD-1 Antibody as an Treatment for EBV-HLH N/A
Recruiting NCT01821781 - Immune Disorder HSCT Protocol Phase 2
Terminated NCT01547143 - Pilot Study of Etoposide-based Therapy and Hematopoietic Cell Transplantation for Hemophagocytic Lymphohistiocytosis N/A
Active, not recruiting NCT00006056 - Pilot Study of Unrelated Donor Hematopoietic Stem Cell Transplantation in Patients With Life Threatening Hemophagocytic Disorders N/A
Terminated NCT00006054 - Allogeneic Bone Marrow Transplantation in Patients With Primary Immunodeficiencies N/A
Recruiting NCT03795909 - Ruxolitinib Combined With Dexamethasone for HLH Phase 1/Phase 2
Recruiting NCT03533790 - DEP-Ru Regimen as a Salvage Therapy for HLH Phase 3
Not yet recruiting NCT05315336 - L-DEP/DEP Regimen and PD-1 Antibody as a Treatment for Relapse/Refractory EBV-HLH Phase 3
Recruiting NCT01793168 - Rare Disease Patient Registry & Natural History Study - Coordination of Rare Diseases at Sanford
Recruiting NCT04326348 - A Study of TQ05105 Tablets in Subjects With Hemophagocytic Lymphohistiocytosis（HLH） Phase 1
Recruiting NCT04551131 - Use Of A Response-Adapted Ruxolitinib-Containing Regimen For The Treatment Of Hemophagocytic Lymphohistiocytosis Phase 1/Phase 2
Recruiting NCT05546060 - Efficacy and Safety of Venetoclax Combined With Dexamethasone and Etoposide in HLH Phase 1
Recruiting NCT04120090 - Ruxolitinib as a Salvage Therapy for Hemophagocytic Lymphohistiocytosis Phase 3